Overview of Dr. Forsberg
Peter Forsberg, MD, is a fellowship-trained, board-certified hematologist/oncologist who has taken a clinical and research focus on the treatment of plasma cell disorders including multiple myeloma, amyloidosis and less common conditions such as Waldenstrom’s Macroglobulinemia. Known for providing high quality, cutting-edge care, Dr. Forsberg is regarded not only as an expert in the field, but also as an expert in building relationships with his patients through empathy, compassion and open communication.
Dr. Forsberg grew up in Littleton, CO, but left the state to complete his undergraduate studies at Washington University in St. Louis, MO. He returned to Colorado for medical school, completing his Doctor of Medicine degree at the University of Colorado School of Medicine. He then diversified his medical training with residency at the Weill-Cornell Medical College/New York-Presbyterian Hospital and served as chief medical resident at Memorial Sloan Kettering Cancer Center before returning to Cornell for fellowship training in hematology and medical oncology. He returned to Colorado once more in 2016 with a passion to bring his home state the highest quality, cutting-edge medical care at a caliber as high as anywhere in the nation.
Today, Dr. Forsberg has established trusted clinical practice while maintaining continuing research so he can bring his patients the most innovative, advanced treatments available. He serves as principle investigator on various clinical trials and has published and presented his work at the national and international level. In clinical practice, Dr. Forsberg believes in collaborative care. First, partnering with his patients— explaining diagnoses, presenting treatment options, and walking alongside them throughout their journeys. Secondly, partnering with his colleagues in the practice and throughout the system of care to create multidisciplinary plans of care that meet the unique needs of each patient.
Office
1721 E 19th Ave Ste 200
Denver, CO 80218
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2013 - 2016
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2012
- University of Colorado School of Medicine Anschutz Medical CampusClass of 2009
Certifications & Licensure
- CO State Medical License 2016 - 2025
- WY State Medical License 2021 - 2025
- CA State Medical License 1964 - 2017
- NY State Medical License 2012 - 2017
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma Start of enrollment: 2021 Nov 18
Roles: Principal Investigator
- A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Roles: Principal Investigator
Publications & Presentations
PubMed
- MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.Lorraine N Davis, Zachary J Walker, Lauren T Reiman, Sarah E Parzych, Brett M Stevens
Clinical Cancer Research. 2024-07-15 - 1 citationsImpact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky
Journal of Hematology & Oncology. 2024-06-06 - 2 citationsEx Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.Alana L Keller, Lauren T Reiman, Olivia Perez de Acha, Sarah E Parzych, Peter A Forsberg
Cancer Research Communications. 2024-03-12
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: